ID   L0301
AC   CVCL_1F89
SY   LO301
DR   Wikidata; Q54900922
RX   DOI=10.2482/haigan.32.223;
RX   PubMed=1484432;
CC   Population: Japanese.
CC   Doubling time: 201 hours (DOI=10.2482/haigan.32.223).
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   30Y
CA   Cancer cell line
DT   Created: 08-07-15; Last updated: 29-06-23; Version: 7
CH   CVCL_1F90 ! L0301/CDDP
//
RX   PubMed=1484432;
RA   Mizusawa, Akio
RT   "Generation of effector cells from primary lung cancer patients by
RT   stimulation with anti-CD3 monoclonal antibody followed by culture with
RT   recombinant interleukin-2.";
RL   Nihon Kyobu Shikkan Gakkai Zasshi 30:1937-1945(1992).
//
RX   DOI=10.2482/haigan.32.223;
RA   Nozawa, Satoru
RT   "Establishment and characterization of multiple drug-resistant lung
RT   cancer cell lines and their susceptibility to autologous effector
RT   lymphocytes.";
RL   Nihon Haigan Gakkai 32:223-232(1992).
//